Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cance...
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patien...
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Xinqiao Hospital of Chongqing
- Target Recruit Count
- 9
- Registration Number
- NCT06556108
- Locations
- 🇨🇳
Department of Hematology, Xinqiao Hospital, ChongQing, Chongqing, China
Emapalumab Prevention of CAR-T Cell Associated Toxicities
- Conditions
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Marcela V. Maus, M.D.,Ph.D.
- Target Recruit Count
- 28
- Registration Number
- NCT06550141
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 85
- Registration Number
- NCT06538012
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Shanghai First Song Biotechnology Co., LTD
- Target Recruit Count
- 9
- Registration Number
- NCT06532630
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- The National Center of Oncology, Azerbaijan
- Target Recruit Count
- 200
- Registration Number
- NCT06531447
- Locations
- 🇦🇿
Elchin Mansurov, Baku, Azerbaijan
Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects With Relapsed/Refractory Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Shanghai First Song Biotechnology Co., LTD
- Target Recruit Count
- 9
- Registration Number
- NCT06532643
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 75
- Registration Number
- NCT06532799
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 85
- Registration Number
- NCT06532812
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 128
- Registration Number
- NCT06533748
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 85
- Registration Number
- NCT06530303
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.